RXRX
Price
$5.29
Change
+$0.20 (+3.93%)
Updated
Apr 2 closing price
Capitalization
2.13B
34 days until earnings call
VERV
Price
$3.91
Change
-$0.23 (-5.56%)
Updated
Apr 2 closing price
Capitalization
347.19M
34 days until earnings call
Ad is loading...

RXRX vs VERV

Header iconRXRX vs VERV Comparison
Open Charts RXRX vs VERVBanner chart's image
Recursion Pharmaceuticals
Price$5.29
Change+$0.20 (+3.93%)
Volume$17.5M
Capitalization2.13B
Verve Therapeutics
Price$3.91
Change-$0.23 (-5.56%)
Volume$2.59M
Capitalization347.19M
RXRX vs VERV Comparison Chart
Loading...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RXRX vs. VERV commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RXRX is a Hold and VERV is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (RXRX: $5.29 vs. VERV: $3.91)
Brand notoriety: RXRX and VERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RXRX: 66% vs. VERV: 193%
Market capitalization -- RXRX: $2.13B vs. VERV: $347.19M
RXRX [@Biotechnology] is valued at $2.13B. VERV’s [@Biotechnology] market capitalization is $347.19M. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RXRX’s FA Score shows that 0 FA rating(s) are green whileVERV’s FA Score has 1 green FA rating(s).

  • RXRX’s FA Score: 0 green, 5 red.
  • VERV’s FA Score: 1 green, 4 red.
According to our system of comparison, both RXRX and VERV are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RXRX’s TA Score shows that 4 TA indicator(s) are bullish while VERV’s TA Score has 4 bullish TA indicator(s).

  • RXRX’s TA Score: 4 bullish, 6 bearish.
  • VERV’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, VERV is a better buy in the short-term than RXRX.

Price Growth

RXRX (@Biotechnology) experienced а -14.26% price change this week, while VERV (@Biotechnology) price change was -27.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.56%. For the same industry, the average monthly price growth was -9.64%, and the average quarterly price growth was -14.03%.

Reported Earning Dates

RXRX is expected to report earnings on May 07, 2025.

VERV is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-7.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.13B) has a higher market cap than VERV($347M). RXRX YTD gains are higher at: -21.746 vs. VERV (-30.674). VERV has higher annual earnings (EBITDA): -221.91M vs. RXRX (-426.72M). RXRX has more cash in the bank: 594M vs. VERV (524M). VERV has less debt than RXRX: VERV (70M) vs RXRX (108M). RXRX has higher revenues than VERV: RXRX (58.5M) vs VERV (32.3M).
RXRXVERVRXRX / VERV
Capitalization2.13B347M613%
EBITDA-426.72M-221.91M192%
Gain YTD-21.746-30.67471%
P/E RatioN/AN/A-
Revenue58.5M32.3M181%
Total Cash594M524M113%
Total Debt108M70M154%
TECHNICAL ANALYSIS
Technical Analysis
RXRXVERV
RSI
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 11 days ago
85%
Bullish Trend 10 days ago
87%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
88%
View a ticker or compare two or three
Ad is loading...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSSYX8.09N/A
N/A
AMG Frontier Small Cap Growth Z
GSIEX28.76N/A
N/A
Goldman Sachs International Eq ESG Instl
FAVFX32.87N/A
N/A
Fidelity Advisor Value A
GSIMX21.23N/A
N/A
Goldman Sachs GQG Ptnrs Intl Opps Instl
SWLGX107.93N/A
N/A
Schwab ® US Large-Cap Growth Idx

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been closely correlated with CRSP. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
+3.83%
CRSP - RXRX
69%
Closely correlated
+3.17%
BEAM - RXRX
62%
Loosely correlated
+4.79%
NTLA - RXRX
58%
Loosely correlated
+9.69%
PRME - RXRX
56%
Loosely correlated
+0.28%
ABSI - RXRX
53%
Loosely correlated
+3.33%
More

VERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, VERV has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if VERV jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VERV
1D Price
Change %
VERV100%
-5.44%
CRSP - VERV
54%
Loosely correlated
+3.17%
BEAM - VERV
53%
Loosely correlated
+4.79%
RXRX - VERV
50%
Loosely correlated
+3.83%
NTLA - VERV
48%
Loosely correlated
+9.69%
IVEVF - VERV
46%
Loosely correlated
N/A
More